linjc16/ctgov huggingface dataset:
Physical Workload Identify in Chest Compression Position Using Surface Electromyogram

Study Overview
=================
Brief Summary
-----------------
The chest compression depth decreases over time after starting continuous chest compression due to the rescuers' fatigue. The investigators hypothesized that the frequency parameters from surface electromyogram from each muscle during chest compression may reflect the muscle fatigue of the rescuers. Then investigators can identify which of the body are mainly used and get tired by continuous chest compression using surface electromyogram.

Conditions
-----------------
Cardiopulmonary Resuscitation, Cardiac Arrest

Intervention / Treatment
-----------------
* Behavioral: chest compression with kneeling position
* Behavioral: chest compression with standing position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: doctors with American Heart Association Basic Life Support (AHA BLS) provider certification healthy, experienced health-care providers Exclusion Criteria: physical pain (ex. low back, wrist) heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group1<br>first : chest compression with kneeling position second : chst compression with standing position | Behavioral: chest compression with kneeling position<br> <br> Behavioral: chest compression with standing position<br> <br> |
| Experimental: Group2<br>first : chest compression with standing position second : chst compression with kneeling position | Behavioral: chest compression with kneeling position<br> <br> Behavioral: chest compression with standing position<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| median frequency of electromyogram | median frequency of electromyogram in 16 muscles during chest compression The muscles are flexor carpi radialis, extensor carpi radialis, biceps brachii, triceps brachii, deltoideus, erector spinae (cervical area), trapezius, rhomboid, erector spinae (thoracic area), erector spinae (lumbar), obliquus externus abdominis, rectus abdominis, pectoralis, quadriceps femoris, biceps femoris, gastrocnemius. On the dominant side of the rescuers, we will attach sixteen electrodes on these muscles. | two weeks |
Apotransferrin in Atransferrinemia

Study Overview
=================
Brief Summary
-----------------
Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.

Official Title
-----------------
Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients

Conditions
-----------------
Congenital Atransferrinemia

Intervention / Treatment
-----------------
* Drug: Human apotransferrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Established diagnosis of atransferrinemia, defined as serum levels of transferrin below 40 mg/dl Informed consent Exclusion Criteria: Known with allergic reactions against human plasma or plasma products Having detectable anti-immunoglobulin A antibodies
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: human apotransferrin<br>intravenous apotransferrin every 4-8 weeks | Drug: Human apotransferrin<br>* intravenous infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobulin | Hemoglobulin within normal range | 10 year | 
| pharmacokinetics of transferrin | serum transferrin levels measured on several time points before and after infusion | first infusion and year 3 | 
| iron overload in organs | Elimination of iron overload (liver, heart) | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Iron overload | Serum Ferritin within normal values | 10 years | 
| Hematocrit | Hematocrit within normal values | 10 years | 
| Erythrocytes | Erythrocytes within normal values | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transferrin, anemia, iron overload
Barlow's unIfied Protocol for emoTional Eating (BITE): a Pre-post Design

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the efficacy of a group intervention program, based on the Barlow's protocol, in patients with emotional eating with the aim of improving the emotional eating pattern. The design is quasi-experimental pre-post with a control group (waiting list) and evaluation of the maintenance of the response after 6 months of the end of the program. Includes outpatients from the Eating Disorders Unit and the Psychiatry Unit of a Hospital. A sample size of 26 participants is considered in the experimental group, and another 26 more in the control group.

Official Title
-----------------
Barlow's unIfied Protocol for emoTional Eating (BITE): a Pre-post Design

Conditions
-----------------
Emotional Eating

Intervention / Treatment
-----------------
* Behavioral: Barlow's Unified Protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Outpatients from eating behavior disorder outpatient clinics and psychiatric outpatient clinics. Age between 18 and 65 years. Score of more than 2.46 on the emotional eating subscale of the DEBQ scale Exclusion Criteria: Diagnosis of active Eating Disorder, that is, without at least 6 months of symptomatic remission or that exceed the cut-off point on the EAT-26 scale. Patients with severe mental disorder with or without psychotic symptoms (schizophreniform disorders, bipolar spectrum disorders, major depression) Patients with some other medical disorder that presents with impulse dysregulation, such as epilepsy, frontal-type dementia... Patients with an IQ < 85 Patients who do not give consent. Patients who do not understand or speak Spanish or Catalan.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Emotional eating intervention<br>Emotional eating intervention | Behavioral: Barlow's Unified Protocol<br>* Adaptation of the cognitive-behavioral Barlow's Unified Protocol for emotional eating pattern.<br>|
| No Intervention: Waiting list<br>Waiting list | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emotional eating score assessed by the Emotional eating sub-scale of the Dutch Eating Behavior Questionnaire (DEBQ-EE) |  | 8 weeks |
Wavefront-guided LASIK for Correction of Myopia

Study Overview
=================
Brief Summary
-----------------
Laser in situ keratomileusis is a successful procedure for the treatment of low to moderate myopia. Advances over the last decade have allowed LASIK to also correct higher order wavefront aberrations. In low myopia, there seem to be a minor effect of such wavefront-guided treatment. However, it remains to be established whether there is a beneficial effect in higher degrees of myopia. The study aims to determine whether myopic subjects (-6 to -10 diopters) with higher-than-average preoperative higher-order aberrations have benefit of wavefront-guided treatment. Subjects are randomized to wavefront-guided treatment in one eye, and conventional treatment in the other.

Official Title
-----------------
Wavefront-guided LASIK for Correction of Myopia

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Procedure: Laser in situ keratomileusis (LASIK)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20 to 50 years No known ocular or systemic disease Not pregnant or breastfeeding Myopia between -6.0 and -10.0 diopters Astigmatism below 2.0 diopters Difference of less than 1.0 diopters in spherical equivalent between eyes Normal corneal topography Corneal thickness sufficient for planned treatment Exclusion Criteria: Patients that do not fulfill inclusion criteria Insufficient quality of ocular wavefront measurement

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Wavefront-guided LASIK<br>One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK. | Procedure: Laser in situ keratomileusis (LASIK)<br>* Wavefront guided treatment in one eye, conventional in the other.<br>* Other names: Device: Carl Zeiss Meditec MEL-80 excimer laser.;|
| Active Comparator: Conventional LASIK<br>One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment. | Procedure: Laser in situ keratomileusis (LASIK)<br>* Wavefront guided treatment in one eye, conventional in the other.<br>* Other names: Device: Carl Zeiss Meditec MEL-80 excimer laser.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ocular higher order aberrations | Hartmann-Schack wavefront aberrometry using the Zeiss Meditec WASCA | 12 months |
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of PEGASYS plus ribavirin in male patients with hemophilia A and chronic hepatitis C. All patients will receive PEGASYS 180 micrograms s.c. weekly plus ribavirin 1000-1200mg p.o. daily (depending on body weight) for 48 weeks. Following treatment there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.

Official Title
-----------------
An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C

Conditions
-----------------
Hepatitis C, Chronic

Intervention / Treatment
-----------------
* Drug: peginterferon alfa-2a [Pegasys]
* Drug: ribavirin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male patients, >=18 years of age; hemophilia A; chronic hepatitis C; compensated liver disease. Exclusion Criteria: therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment <=6 months before start of study drug; hepatitis A, hepatitis B or HIV infection; chronic liver disease other than chronic hepatitis C.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: peginterferon alfa-2a [Pegasys]<br>* 180 micrograms sc weekly for 48 weeks<br>Drug: ribavirin<br>* 1000/1200mg po daily for 48 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SVR |  | Week 72 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AEs, laboratory parameters. |  | Throughout study |
Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether photodynamic therapy or CO2 laser therapy is superior in the treatment of actinic keratoses with respect to efficacy and side effects.

Detailed Description
-----------------
Ablative laser therapy and photodynamic therapy are widely used and accepted therapeutic methods to treat multiple actinic keratoses, yet comparative studies are rare. The purpose of this study is to compare both treatments intraindividually with respect to treatment efficacy and side effects.

Official Title
-----------------
Prospective, Single-center, Investigator-blinded, Randomized, Half-side, Comparative Study of Photodynamic Therapy vs. CO2 Laser Therapy in Treatment of Actinic Keratoses

Conditions
-----------------
Actinic Keratosis

Intervention / Treatment
-----------------
* Procedure: ablative CO2 laser therapy
* Procedure: photodynamic therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women with clinical and histological diagnosed, symmetrical distributed actinic keratoses at least 2 actinic keratoses, on each of both treatment areas at least one Patients must be 18 years or older. Exclusion Criteria: Age 17 years or younger lack of patient's informed consent for any of the two treatments contraindication for Co2 therapy or for photodynamic therapy skin infection in the treatment area

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: ablative CO2 laser therapy|CO2 laser therapy|
|Procedure: photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of actinic keratoses 3 months after treatment |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histologic features |  | 1 month after therapy | 
| Epidermal thickness in optical coherence tomography |  | 1 month after therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
actinic keratosis, field cancerisation
Glycine Treatment of Prodromal Symptoms

Study Overview
=================
Brief Summary
-----------------
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.

Official Title
-----------------
Glycine Treatment of Prodromal Symptoms

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: glycine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 14-35 meets SIPS criteria for psychosis prodrome Exclusion Criteria: current antipsychotic medication more than 4 weeks of antipsychotic medication lifetime

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: glycine<br>* 0.8 g/kg/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scale Of Prodromal Symptoms total score |  | 8 weeks |
HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Study Overview
=================
Brief Summary
-----------------
HYPID-2 study is an extension of HYPID study (NCT01443598) : HYPID-2 is also an observational and prospective study of patients with interstitial lung disease and pre capillary hypertension diagnosed by right heart sided catheterization. It concerns only incident patients (i.e patients included within 6 months after PH diagnosis) whereas HYPID concerned prevalent and incident cases. The primary aim is the same than HYPID : identify prognostic factors

Detailed Description
-----------------
Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse interstitial lung disease. In this context, PH represents an important factor of morbidity and mortality for these patients. As in HYPID, the main purpose of HYPID-2 is to determine predictive factors of mortality within this cohort of incident patients (i.e patients included within 6 months after PH diagnosis). In order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of incident patients. Each incident patient will be followed during 2 years at least.

Official Title
-----------------
Observational Study of Incident Patients With Pre Capillary Pulmonary Hypertension and Interstitial Lung Disease

Conditions
-----------------
Pulmonary Arterial Hypertension, Diffuse Interstitial Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients newly diagnosed with: Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP > or = 25 mmHg, PCWP < or = 15 mmHg Interstitial lung disease with diffuse infiltrative opacities on chest CT scan Exclusion Criteria: Pulmonary hypertension related to a thromboembolic disease Respiratory disease other than diffuse interstitial lung disease Any etiological factor of pulmonary arterial hypertension based on NICE 2013 classification other than diffuse interstitial lung disease Any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Determine predictive factors of mortality | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Time to death or 10% decline in FVC | 2 years | 
| Response to therapy | Proposition of patients with 10% or more decline in PVR | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary arterial hypertension, Interstitial lung disease at HRCT
The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

Study Overview
=================
Brief Summary
-----------------
Double blind, randomized, placebo control, multiple dose, dose escalation study

Detailed Description
-----------------
A phase I clinical study, randomized, double-blind, placebo-controlled, multiple doses, dose escalation study of the safety, tolerability and pharmacokinetics/pharmacodynamics of JPI-289 in healthy male volunteers.

Official Title
-----------------
A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers.

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Drug: JPI-289
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19 55 years healthy male BMI measurement 20kg/m² 27kg/m² 90 ≤ SBP<140(mmHg) 60 ≤ DBP<100(mmHg) 45 ≤ Pulse rate<100(bpm) Signed the informed consent form to participate voluntarily and to comply with the trial requirements For a follow-up visit and during the study period, blood samples and availability Exclusion Criteria: History of clinically significant hepatic, gastrointestinal, pulmonary, musculoskeletal, endocrine, psychiatric, hematooncologic, cardiovascular (Specially asthma, obstructive pulmonary disease, peptic ulcer) History of skin disease of graft affecting absorption of the drug History of drug abuse Positive urine drug screening Administrated investigational product in a previous clinical trial within 60 days of the screening test Donated blood within 60 days prior to screening test

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: JPI-289<br>Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort) | Drug: JPI-289<br>* PARP-1 inhibitor<br>|
| Placebo Comparator: Placebo<br>Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort) | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUCτ,ss and Cmax,ss(76h), Relative PAR level(73h,%) |  | 96 hours, 73 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cav,ss |  | 96 hours | 
| t1/2β |  | 96 hours | 
| Vd,ss |  | 96 hours | 
| CL |  | 96 hours |